Meeting
2024 ASCO Annual Meeting
Clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in patients (pts) with checkpoint inhibitor (CPI) –pretreated advanced/metastatic non-small cell lung cancer (NSCLC): Preliminary results of a P2 trial.
Presenter
Timothy Larson, MD
Minnesota Oncology Hematology P.A.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04880863
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8615)
DOI
10.1200/JCO.2024.42.16_suppl.8615
Abstract #
8615
Poster Bd #
479
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.
Speaker: Christian Grohé
Videos & Slides
2020 ASCO Virtual Scientific Program
Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): Updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02392455).
Speaker: Christian Grohé
Videos & Slides
2024 ASCO Annual Meeting
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
Speaker: Tony S. K. Mok, MD, FRCPC, FASCO
Videos & Slides
2024 ASCO Annual Meeting
Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC.
Speaker: Ravi Bharat Parikh, MD, MPP